Despite posting an estimate-beating 70 percent rise in third quarter net profit, slowing sales growth for Gilead Sciences Inc.'s hepatitis C virus (HCV) drugs attributed to payer restrictions weighed on company shares (NASDAQ:GILD), which slid $2.83, to close at $108.13 on Wednesday.